Our growth strAtegy
Our future growth will be achieved by focusing on the following key areas:
Substantial increase in market access
STRATEGY
We intend to drive revenue in the short term by focusing on distribution of Harpinαβ and PHC279 by aligning with large distributors with broad market access. We plan to expand sales in broad acre crops and vegetables where our products provide the most benefit to farmers, including sugar cane, corn, soy, citrus, rice, almonds and grapes.
With the launch of Saori® in Brazil, we have gained access to the 99 million acre Brazilian soybean market.
Launching peptide products from our PREtec platforms
STRATEGY
Our target is to launch at least one PREtec product in a major market every year. The launch of Saori® in Brazil in 2021 was the first, followed in 2023 by the US launch of PHC279 under the brand Obrona™ into corn and specialty crops with Wilbur-Ellis.
Further building the capability to deliver additional products from PREtec
STRATEGY
The Group made a significant capital investment by building a pilot plant facility in our Seattle location. This allows the Group to produce peptides on a pilot scale and assist with developing and optimising manufacturing methods. The Group also secured a production facility for PHC279, which led to the achievement of our volume cost targets.
IP protection and ongoing innovation
STRATEGY
The Group has an extensive library of PREtec peptides, which can be further expanded. The Group has now been granted multiple patents for PREtec peptides by the USPTO and international patent offices; numerous filings are in the process of being reviewed around the world, as the Group builds its IP portfolio.
The Group has been issued 18 patents and more than 50 applications in 11 countries and the European Patent Office.
5
6
Consolidation
STRATEGY
The Group is well positioned to take a lead in consolidating this fragmented sector, due to its strong portfolio and market access.
Sustainability
STRATEGY
The Group’s products contribute to sustainable agriculture. Harpinαβ and PREtec peptides have been classified as “low toxicity” products, are exempt from the requirement to establish maximum residue limits (MRLs), and quality for ‘fast track’ regulatory approval in the USA and Brazil.
